These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12716370)

  • 21. Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases.
    Yamada M; Miyamura K; Fujiwara T; Yokoyama H; Tomiya Y; Ishizawa K; Harigae H; Kameoka J; Sasaki T
    Tohoku J Exp Med; 2004 Sep; 204(1):79-84. PubMed ID: 15329466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging.
    Kreuzer KA; Klühs C; Baskaynak G; Movassaghi K; Dörken B; le Coutre P
    Br J Haematol; 2004 Jan; 124(2):195-9. PubMed ID: 14687030
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
    Khoury HJ; Kukreja M; Goldman JM; Wang T; Halter J; Arora M; Gupta V; Rizzieri DA; George B; Keating A; Gale RP; Marks DI; McCarthy PL; Woolfrey A; Szer J; Giralt SA; Maziarz RT; Cortes J; Horowitz MM; Lee SJ
    Bone Marrow Transplant; 2012 Jun; 47(6):810-6. PubMed ID: 21986636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
    Pulsipher MA
    Pediatr Blood Cancer; 2004 Oct; 43(5):523-33. PubMed ID: 15382266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
    Barton JC; Jones SC; Lamberth WC; Reymann MT; Scott VC
    Am J Hematol; 2002 Oct; 71(2):139-40. PubMed ID: 12353320
    [No Abstract]   [Full Text] [Related]  

  • 27. [Tolerability of imatinib for patients with chronic myelogeneous leukemia (CML)].
    Imataki O; Shintani T; Waki F; Ohnishi H; Ishida T
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1863-7. PubMed ID: 19011333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 30. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 31. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase.
    Jiang Q; Xu LP; Liu DH; Liu KY; Chen SS; Jiang B; Jiang H; Chen H; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Lai YY; Huang XJ
    Blood; 2011 Mar; 117(11):3032-40. PubMed ID: 21252092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
    Goldman J
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing treatment of chronic myeloid leukemia: a rational approach.
    Stone RM
    Oncologist; 2004; 9(3):259-70. PubMed ID: 15169981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
    Rytting ME; Wierda WG
    Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Lim D; Muir J
    Lancet; 2001 Dec; 358(9296):1903. PubMed ID: 11741656
    [No Abstract]   [Full Text] [Related]  

  • 36. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
    Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
    Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia.
    Lokeshwar N; Kumar L; Kumari M
    Leuk Lymphoma; 2005 May; 46(5):781-4. PubMed ID: 16019519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience.
    Olavarria E; Kanfer E; Szydlo R; O'Brien S; Craddock C; Apperley J; Goldman J
    Br J Haematol; 2000 Mar; 108(4):769-77. PubMed ID: 10792282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia.
    Zhang GF; Zhou M; Bao XB; Qiu HY; Li Z; Xue SL
    Asian Pac J Cancer Prev; 2016; 17(9):4477-4481. PubMed ID: 27797264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precipitation of porphyria cutanea tarda by imatinib mesylate?
    Ho AY; Deacon A; Osborne G; Mufti GJ
    Br J Haematol; 2003 Apr; 121(2):375. PubMed ID: 12694262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.